It’s last call for presentations at the Midwest Drug Development conference, officials announced today.
Only 10 slots remain open in the two-day slate of early- and mid-stage technologies that will be presented to guests from the worlds of biomedical therapeutics and investor groups.
More than a dozen major Midwest universities have committed to lifting the curtain on 44 technologies in a series of 10-minute presentations that will span two days in Omaha, Oct. 1-2.
They will cover a wide scope of conditions and diseases, including cancer, infectious diseases and central nervous disorders, to name a few. To learn more about how to apply for one of the last presentaion spots, contact Matt Boehm at mboehm@unmc.edu.
Planners expect the conference will provide industry and investors a singular event to learn about cutting edge Midwestern therapeutic technologies and start-up companies. Academic researchers will also have the opportunity to find partners that can help further develop future cures and treatments.
The conference will also include ample networking opportunities and dedicated spaces where guests can set up one-on-one partnering meetings and showcase other technologies.
So far the list of participating universities includes Nebraska and the Nebraska Medical Center, Kansas, Kansas State, Iowa, Iowa State, Illinois, Indiana, Purdue, Washington University, and Colorado State.
Registration is $500, but a limited number of discounts codes are available for select industry an investor groups. Register here or contact Matt Boehm at mboehm@unmc.edu to learn how to receive a discount code. The event is primarily sponsored and hosted by UNeMed and the University of Nebraska.
